Overview

Advancing the treatment of hematologic diseases


At PharmaEssentia, we are focused on providing new best-in-class therapeutic solutions for patients with myeloproliferative neoplasms (MPNs) and other hematologic diseases.

Addressing unmet treatment needs

Myeloproliferative neoplasms are a group of rare, chronic blood cancers that cause the bone marrow to produce too many blood cells. Patients with MPNs have historically had limited treatment options, and these diseases can result in chronic symptom burden, risk of health complications, including progression to more aggressive forms of cancer.


Our researchers are working diligently to provide physicians and patients with tolerable, effective, long-term treatments that aim to improve patient outcomes and reduce the risk of disease progression.

Innovating across the full spectrum of MPNs

There are several types of MPNs, each with unique characteristics and challenges. We’re working to develop solutions across the full range of these rare blood cancers.


View our development pipeline:

  • Polycythemia Vera (PV)

    Polycythemia vera (PV) is characterized by the overproduction of red blood cells, which can increase blood viscosity and raise the risk of blood clots.

    Learn More
  • Essential Thrombocythemia (ET)

    ET is characterized by the overproduction of platelets (thrombocytes), which can cause possible thrombotic and hemorrhagic complications.

    Learn More
  • Early Primary Myelofibrosis (Early PMF)

    Primary myelofibrosis (PMF) is a rare blood cancer where bone marrow scarring (fibrosis) disrupts blood cell production. Symptoms include anemia and splenomegaly. It is a myeloproliferative neoplasm often linked to JAK2 mutations and can progress to AML.

    Learn More